Table 1.

Baseline characteristics of patients identified with exon 19 deletions or L858R point mutations

Exon 19 deletions (N = 22)L858R (N = 10)P
Sex, n (%)1.00
    Male8 (36)4 (40)
    Female14 (64)6 (60)
Age, median (range)65.5 (44-81)70 (32-79)0.78
Race, n (%)1.00
    White, non-Hispanic18 (82)9 (90)
    Hispanic1 (5)1 (10)
    Asian2 (9)0
    Black00
    Other1 (5)0
Performance status, n (%)0.39 (0-1 vs 2-3)
    01 (5)3 (30)
    115 (68)6 (60)
    21 (5)1 (10)
    35 (23)0 (0)
Smoking history, n (%)1.00
    None10 (45)5 (50)
    Former12 (55)5 (50)
    Current00
Histology, n (%)0.33
    Adeno (non-BAC)13 (59)7 (70)
    Adeno with BAC4 (18)0
    BAC4 (18)1 (10)
    Other1 (5)2 (20)
No. prior chemotherapies, n (%)0.65
    09 (41)7 (70)
    15 (23)1 (10)
    23 (14)1 (10)
    32 (9)1 (10)
    43 (14)0
EGFR-TKI, n (%)0.10
    Gefitinib18 (82)5 (50)
    Erlotinib4 (18)5 (50)
  • NOTE: Due to rounding, some cells do not add to 100%.

    Abbreviation: BAC, bronchioloalveolar carcinoma.